Roche is stuck on molecular glue
BioPharma
Source: biopharmadive.com
Page 2 - Markus Warmuth News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Markus Warmuth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Markus Warmuth Today - Breaking & Trending Today
Roche Deal Aims to Get Molecular Glues to Stick to Elusive Cancer, Neuro Targets
Roche is paying $50 million up front to begin a drug R&D alliance with Monte Rosa Therapeutics, a biotech whose molecular glue technology could address targets previously deemed undruggable. It’s Roche’s second such deal in the past month.
Source: medcitynews.com
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors - Monte Rosa Therapeutics (NASDAQ:GLUE)
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the
Source: benzinga.com
Candidate therapy MRT-6160 chosen for MS, other autoimmune diseases | Multiple Sclerosis News Today
MRT-6160 has been selected for development by Monte Rosa Therapeutics for the treatment of multiple sclerosis and other autoimmune disorders.
Source: multiplesclerosisnewstoday.com
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
23.05.2023 - Preclinical data establish MRT-6160’s ability to potently and selectively degrade VAV1 and inhibit disease progression in autoimmunity models, supporting potential applications across multiple autoimmune diseasesPlanned IND filing in the first half ... Seite 1
Source: wallstreet-online.de